• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

补体激活片段 C4a 通过与蛋白酶激活受体 1 和 4 结合作为无束缚激动剂来介导效应功能。

Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4.

机构信息

Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.

Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104;

出版信息

Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):10948-10953. doi: 10.1073/pnas.1707364114. Epub 2017 Sep 26.

DOI:10.1073/pnas.1707364114
PMID:28973891
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5642699/
Abstract

C4a is a small protein released from complement component C4 upon activation of the complement system's classical and lectin pathways, which are important constituents of innate immune surveillance. Despite the structural similarity between C4a and well-described anaphylatoxins C3a and C5a, the binding partner and biological function of C4a have remained elusive. Using a cell-based reporter assay, we screened C4a against a panel of both known and orphan G protein-coupled receptors and now provide evidence that C4a is a ligand for protease-activated receptor (PAR)1 and PAR4. Whereas C4a showed no activity toward known anaphylatoxin receptors, it acted as an agonist for both PAR1 and PAR4 with nanomolar activity. In human endothelial cells, ERK activation by C4a was mediated through both PAR1 and PAR4 in a Gα-independent signaling pathway. Like other PAR1 activators, C4a induced calcium mobilization through the PAR1/Gα/PLCβ signaling axis. Moreover, C4a increased stress fiber formation and enhanced endothelial permeability, both of which were reduced by PAR1 antagonists. In sum, our study identifies C4a as an untethered agonist for PAR1 and PAR4 with effects on cellular activation and endothelial permeability, thereby revealing another instance of cross-talk between the complement system and other host defense pathways.

摘要

C4a 是补体成分 C4 在补体系统经典途径和凝集素途径激活时释放的一种小蛋白,这两条途径是先天免疫监视的重要组成部分。尽管 C4a 在结构上与描述明确的过敏毒素 C3a 和 C5a 相似,但 C4a 的结合伴侣和生物学功能仍然难以捉摸。我们使用基于细胞的报告基因检测方法,在一组已知和孤儿 G 蛋白偶联受体中对 C4a 进行了筛选,现在提供了证据表明 C4a 是蛋白酶激活受体 (PAR)1 和 PAR4 的配体。虽然 C4a 对已知的过敏毒素受体没有活性,但它对 PAR1 和 PAR4 均具有纳摩尔活性的激动剂作用。在人内皮细胞中,C4a 通过 PAR1 和 PAR4 介导 ERK 激活,这是一种不依赖于 Gα 的信号通路。与其他 PAR1 激活剂一样,C4a 通过 PAR1/Gα/PLCβ 信号轴诱导钙动员。此外,C4a 增加了应力纤维形成并增强了内皮通透性,而这两种作用均被 PAR1 拮抗剂所降低。总之,我们的研究确定 C4a 是 PAR1 和 PAR4 的无束缚激动剂,对细胞激活和内皮通透性有影响,从而揭示了补体系统与其他宿主防御途径之间的另一种串扰。

相似文献

1
Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4.补体激活片段 C4a 通过与蛋白酶激活受体 1 和 4 结合作为无束缚激动剂来介导效应功能。
Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):10948-10953. doi: 10.1073/pnas.1707364114. Epub 2017 Sep 26.
2
Complement factor C4a does not activate protease-activated receptor 1 (PAR1) or PAR4 on human platelets.补体因子C4a不会激活人血小板上的蛋白酶激活受体1(PAR1)或蛋白酶激活受体4(PAR4)。
Res Pract Thromb Haemost. 2020 Dec 4;5(1):104-110. doi: 10.1002/rth2.12459. eCollection 2021 Jan.
3
Characterization and functional activity of thrombin receptors in the human lens.人晶状体中凝血酶受体的表征与功能活性
Invest Ophthalmol Vis Sci. 2005 Mar;46(3):925-32. doi: 10.1167/iovs.04-0523.
4
Protease activated receptors 1 and 4 sensitize TRPV1 in nociceptive neurones.蛋白酶激活受体 1 和 4 可使伤害感受神经元中的 TRPV1 敏感化。
Mol Pain. 2010 Sep 27;6:61. doi: 10.1186/1744-8069-6-61.
5
Differential actions of PAR2 and PAR1 in stimulating human endothelial cell exocytosis and permeability: the role of Rho-GTPases.蛋白酶激活受体2(PAR2)和蛋白酶激活受体1(PAR1)在刺激人内皮细胞胞吐作用和通透性方面的差异作用:Rho鸟苷三磷酸酶的作用
Circ Res. 2003 Feb 21;92(3):272-8. doi: 10.1161/01.res.0000057386.15390.a3.
6
Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.蛋白酶激活受体1和4介导凝血酶对人血小板的激活作用。
J Clin Invest. 1999 Mar;103(6):879-87. doi: 10.1172/JCI6042.
7
PAR1-stimulated platelet releasate promotes angiogenic activities of endothelial progenitor cells more potently than PAR4-stimulated platelet releasate.PAR1 刺激的血小板释放物比 PAR4 刺激的血小板释放物更有效地促进内皮祖细胞的血管生成活性。
J Thromb Haemost. 2015 Mar;13(3):465-76. doi: 10.1111/jth.12815. Epub 2015 Jan 31.
8
Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets.蛋白酶激活受体PAR1和PAR4对凝血酶诱导的人血小板糖蛋白IIbIIIa激活的作用
Mol Pharmacol. 2017 Jan;91(1):39-47. doi: 10.1124/mol.116.106666. Epub 2016 Oct 26.
9
Green tea polyphenol epigallocatechin-3-gallate inhibits thrombin-induced hepatocellular carcinoma cell invasion and p42/p44-MAPKinase activation.绿茶多酚表没食子儿茶素没食子酸酯抑制凝血酶诱导的肝癌细胞侵袭和p42/p44-丝裂原活化蛋白激酶激活。
Oncol Rep. 2009 May;21(5):1261-7. doi: 10.3892/or_00000349.
10
Activation of PAR4 induces a distinct actin fiber formation via p38 MAPK in human lung endothelial cells.PAR4的激活通过p38丝裂原活化蛋白激酶在人肺内皮细胞中诱导形成独特的肌动蛋白纤维。
J Histochem Cytochem. 2005 Sep;53(9):1121-9. doi: 10.1369/jhc.4A6592.2005. Epub 2005 May 27.

引用本文的文献

1
Platelets in infection: intrinsic roles and functional outcomes.感染中的血小板:内在作用与功能结果
Front Immunol. 2025 Jul 7;16:1616783. doi: 10.3389/fimmu.2025.1616783. eCollection 2025.
2
The Complement System.补体系统
Adv Exp Med Biol. 2025;1476:147-198. doi: 10.1007/978-3-031-85340-1_7.
3
Comparison of the proteomic landscape in experimental ischemia reperfusion with versus without ischemic preconditioning.有缺血预处理与无缺血预处理的实验性缺血再灌注中蛋白质组学格局的比较。
Sci Rep. 2025 Apr 7;15(1):11836. doi: 10.1038/s41598-025-90735-4.
4
Action of the Terminal Complement Pathway on Cell Membranes.补体终末途径对细胞膜的作用。
J Membr Biol. 2025 Mar 23. doi: 10.1007/s00232-025-00343-6.
5
Immunity and Coagulation in COVID-19.新型冠状病毒肺炎中的免疫与凝血。
Int J Mol Sci. 2024 Oct 19;25(20):11267. doi: 10.3390/ijms252011267.
6
C3a Mediates Endothelial Barrier Disruption in Brain-Derived, but Not Retinal, Human Endothelial Cells.C3a 介导脑源性而非视网膜源人内皮细胞的内皮屏障破坏。
Int J Mol Sci. 2024 Oct 19;25(20):11240. doi: 10.3390/ijms252011240.
7
Unraveling the Intricate Web: Complement Activation Shapes the Pathogenesis of Sepsis-Induced Coagulopathy.解开复杂的谜团:补体激活塑造了脓毒症诱导的凝血障碍的发病机制。
J Innate Immun. 2024;16(1):337-353. doi: 10.1159/000539502. Epub 2024 May 31.
8
Pathological mechanisms and future therapeutic directions of thrombin in intracerebral hemorrhage: a systematic review.凝血酶在脑出血中的病理机制及未来治疗方向:一项系统综述
Front Pharmacol. 2024 Apr 18;15:1293428. doi: 10.3389/fphar.2024.1293428. eCollection 2024.
9
Endothelial Cell Calcium Influx Mediates Trauma-induced Endothelial Permeability.内皮细胞钙内流介导创伤诱导的内皮通透性。
Ann Surg. 2025 Apr 1;281(4):671-681. doi: 10.1097/SLA.0000000000006164. Epub 2023 Dec 11.
10
Complement: Functions, location and implications.补体:功能、定位和意义。
Immunology. 2023 Oct;170(2):180-192. doi: 10.1111/imm.13663. Epub 2023 May 24.

本文引用的文献

1
Endothelial cells: source, barrier, and target of defensive mediators.内皮细胞:防御介质的来源、屏障和靶标。
Immunol Rev. 2016 Nov;274(1):307-329. doi: 10.1111/imr.12479.
2
Complement in disease: a defence system turning offensive.补体系统在疾病中的作用:防御系统转为进攻。
Nat Rev Nephrol. 2016 Jul;12(7):383-401. doi: 10.1038/nrneph.2016.70. Epub 2016 May 23.
3
Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway.系统性红斑狼疮与补体经典途径早期成分缺陷
Front Immunol. 2016 Feb 24;7:55. doi: 10.3389/fimmu.2016.00055. eCollection 2016.
4
Protective effect of C4a against hyperoxic lung injury via a macrophage-dependent but not a neutrophil/lymphocyte-dependent signaling pathway.C4a 通过一种巨噬细胞依赖性而非中性粒细胞/淋巴细胞依赖性信号通路对高氧肺损伤的保护作用。
Mol Med Rep. 2016 Feb;13(2):1250-6. doi: 10.3892/mmr.2015.4651. Epub 2015 Dec 7.
5
C4a: An Anaphylatoxin in Name Only.C4a:徒有虚名的过敏毒素。
J Innate Immun. 2015;7(4):333-9. doi: 10.1159/000371423. Epub 2015 Feb 6.
6
Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation.补体 MASP-1 在先天免疫反应和凝血界面的多种作用。
Mol Immunol. 2014 Oct;61(2):69-78. doi: 10.1016/j.molimm.2014.05.013. Epub 2014 Jun 14.
7
Complement anaphylatoxin C4a inhibits C5a-induced neointima formation following arterial injury.补体过敏毒素C4a抑制动脉损伤后C5a诱导的新生内膜形成。
Mol Med Rep. 2014 Jul;10(1):45-52. doi: 10.3892/mmr.2014.2176. Epub 2014 Apr 24.
8
Minireview: Targeting GPCR Activated ERK Pathways for Drug Discovery.综述:靶向GPCR激活的ERK通路进行药物研发。
Curr Chem Genom Transl Med. 2013 Jul 26;7:9-15. doi: 10.2174/2213988501307010009. eCollection 2013.
9
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors.国际基础和临床药理学联合会。[更正]。LXXXVII. 补体肽 C5a、C4a 和 C3a 受体。
Pharmacol Rev. 2013 Jan;65(1):500-43. doi: 10.1124/pr.111.005223.
10
Inhibitory effects of C4a on chemoattractant and secretagogue functions of the other anaphylatoxins via Gi protein-adenylyl cyclase inhibition pathway in mast cells.C4a 通过 Gi 蛋白-腺苷酸环化酶抑制途径抑制肥大细胞中其他过敏毒素趋化作用和分泌作用。
Int Immunopharmacol. 2012 Jan;12(1):158-68. doi: 10.1016/j.intimp.2011.11.006. Epub 2011 Dec 7.